Wall Street analysts expect that Masimo Co. (NASDAQ:MASI) will announce $201.63 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for Masimo’s earnings, with the lowest sales estimate coming in at $201.33 million and the highest estimate coming in at $202.20 million. Masimo posted sales of $183.20 million during the same quarter last year, which suggests a positive year-over-year growth rate of 10.1%. The firm is expected to report its next quarterly earnings results on Tuesday, February 13th.

On average, analysts expect that Masimo will report full year sales of $201.63 million for the current fiscal year, with estimates ranging from $774.25 million to $775.10 million. For the next fiscal year, analysts expect that the company will post sales of $828.13 million per share, with estimates ranging from $810.90 million to $837.85 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Masimo.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.17. The company had revenue of $193.69 million during the quarter, compared to the consensus estimate of $189.01 million. Masimo had a net margin of 45.83% and a return on equity of 22.17%. The company’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.52 earnings per share.

Several analysts have commented on MASI shares. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $98.00 target price for the company in a research report on Thursday, November 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $108.00 target price on shares of Masimo in a research report on Friday, November 3rd. BTIG Research raised shares of Masimo from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Monday, August 14th. Finally, BidaskClub downgraded shares of Masimo from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $97.17.

In related news, EVP Yongsam Lee sold 18,198 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $88.85, for a total transaction of $1,616,892.30. Following the completion of the sale, the executive vice president now directly owns 70,800 shares of the company’s stock, valued at approximately $6,290,580. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Steven Barker sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total transaction of $900,000.00. Following the sale, the director now directly owns 73,249 shares of the company’s stock, valued at $6,592,410. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,074 shares of company stock valued at $4,737,245. 13.10% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Masimo by 7.5% during the 2nd quarter. BlackRock Inc. now owns 7,915,230 shares of the medical equipment provider’s stock worth $721,710,000 after buying an additional 550,995 shares during the period. Vanguard Group Inc. boosted its holdings in Masimo by 6.9% in the 2nd quarter. Vanguard Group Inc. now owns 4,935,693 shares of the medical equipment provider’s stock valued at $450,036,000 after purchasing an additional 318,060 shares during the period. State Street Corp boosted its holdings in Masimo by 10.4% in the 2nd quarter. State Street Corp now owns 1,547,728 shares of the medical equipment provider’s stock valued at $141,121,000 after purchasing an additional 146,212 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Masimo by 3.6% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,113,113 shares of the medical equipment provider’s stock valued at $101,494,000 after purchasing an additional 38,991 shares during the period. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in Masimo by 27.1% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 1,095,353 shares of the medical equipment provider’s stock valued at $99,872,000 after purchasing an additional 233,412 shares during the period. 83.74% of the stock is owned by institutional investors and hedge funds.

Shares of Masimo (NASDAQ MASI) opened at $88.47 on Tuesday. The company has a market cap of $4,592.53, a P/E ratio of 34.05, a price-to-earnings-growth ratio of 2.99 and a beta of 0.72. Masimo has a 1 year low of $60.31 and a 1 year high of $104.71.

ILLEGAL ACTIVITY NOTICE: “Masimo Co. (MASI) Expected to Announce Quarterly Sales of $201.63 Million” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/05/masimo-co-masi-expected-to-announce-quarterly-sales-of-201-63-million.html.

About Masimo

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co. and related companies with MarketBeat.com's FREE daily email newsletter.